Drug administration
The setup of the study followed a within‐subjects, double‐blind, placebo‐controlled, counterbalanced crossover design in which 24 IU of OXT was administered (Syntocinon nasal spray; Defiante Farmacêutica, S.A.). Participants self‐administered three puffs (4 IU per puff) per nostril under supervision of the experiment leader. The placebo consisted of an NaCl solution produced by the pharmacist of the University Medical Centre Utrecht in accordance with GCP guidelines.